Buy, Sell Or Hold ZyVersa Therapeutics Inc (NASDAQ:ZVSA) At $5.45?

ZM Stock

In last trading session, ZyVersa Therapeutics Inc (NASDAQ:ZVSA) saw 0.37 million shares changing hands with its beta currently measuring 0.66. Company’s recent per share price level of $5.45 trading at -$0.29 or -5.05% at ring of the bell on the day assigns it a market valuation of $4.14M. That closing price of ZVSA’s stock is at a discount of -3952.29% from its 52-week high price of $220.85 and is indicating a premium of 18.53% from its 52-week low price of $4.44. Taking a look at company’s average trading volume volume of 394.96K if we extend that period to 3-months.

ZyVersa Therapeutics Inc (NASDAQ:ZVSA) trade information

Upright in the red during last session for losing -5.05%, in the last five days ZVSA remained trading in the green while hitting it’s week-highest on Monday, 04/29/24 when the stock touched $5.45 price level, adding 18.66% to its value on the day. ZyVersa Therapeutics Inc’s shares saw a change of -39.44% in year-to-date performance and have moved 9.22% in past 5-day. ZyVersa Therapeutics Inc (NASDAQ:ZVSA) showed a performance of -26.39% in past 30-days.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

ZyVersa Therapeutics Inc (ZVSA) estimates and forecasts

Statistics highlight that ZyVersa Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -82.64% of value to its shares in past 6 months, showing an annual growth rate of 98.44% while that of industry is 12.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

ZVSA Dividends

ZyVersa Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.